Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.